United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

24 Mar 2017
Change (% chg)

€-0.11 (-0.74%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Almirall says regulatory filing for Tildrakizumab in Europe is validated
Friday, 24 Mar 2017 02:57am EDT 

Almirall SA :The company and Sun Pharma announce validation of regulatory filing for Tildrakizumab, an antibody designed for treatment of moderate-to-severe plaque psoriasis, by the European Medicines Agency (EMA).  Full Article

Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall
Friday, 24 Mar 2017 12:53am EDT 

Sun Pharmaceutical Industries Ltd : Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall. . Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. .Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients.  Full Article

Almirall appoints new chief scientific officer
Friday, 17 Mar 2017 03:16am EDT 

Almirall SA :Appoints dermatologist Bhushan Hardas as chief scientific officer and executive vice president research and development, starting in April 2017.  Full Article

Astrazeneca signs deal with Circassia over Almirall's products
Friday, 17 Mar 2017 03:13am EDT 

Almirall SA : Astrazeneca enters into a strategic collaboration with Circassia for the development and commercialization of Tudorza and Duaklir in the United States [nFWN1GT0XB] . Says Tudorza, Duaklir are products licensed by Almirall to Astrazeneca in an agreement from July 30, 2014 .Under terms of collaboration, Circassia will lead promotion of Tudorza in the US and has been granted an option to gain full commercial rights in the future.  Full Article

Almirall and Symatese enter into collaboration for development of aesthetics products
Thursday, 16 Mar 2017 02:56am EDT 

Almirall SA : Almirall and Symatese enter into a global strategic collaboration for development and commercialization of products in the aesthetics field . Symatese grants Almirall exclusive license for commercialization of hyaluronic acid facial fillers worldwide in exchange of upfront payment of 7.5 million euros ($8.0 million) and subsequent event milestones, royalties and sales milestones .This agreement reinforces Almirall's strategy to continue building a presence in aesthetic medicine.  Full Article

Almirall presents new data from Tildrakizumab clinical development program
Tuesday, 7 Mar 2017 11:32am EST 

Almirall SA : Says presented new analyses of phase 1 and pivotal phase 3 clinical trials of Tildrakizumab, an inhibitor IL-23p19 which is currently being evaluated in patients with moderate-to-severe plaque psoriasis, during an annual meeting of American Academy of Dermatology .Says data from clinical trials demonstrates long-term efficacy of Tildrakizumab.  Full Article

Almirall to amortize senior bonds due 2021, signs revolving credit facility
Monday, 27 Feb 2017 02:59am EST 

Almirall SA : To amortize senior 4.625 percent bonds issued on March 27, 2014 in the amount of 324 million euros ($342.5 million) and maturing in 2021 .Says signs revolving credit facility for up to 250 million euros, over a period of 4 years, with an average interest of less than 1 percent.  Full Article

Almirall EBITDA grows 10.6 pct in FY 2016
Monday, 27 Feb 2017 02:42am EST 

Almirall SA : FY EBITDA up 10.6 percent at 227.6 million euros ($240.5 million) versus 205.7 million euros year ago . FY net profit down 42.7 percent at 75.5 million euros versus 131.8 million euros year ago . FY revenue up 11.7 percent at 859.3 million euros versus 769.0 million euros year ago . To propose dividend of 0.19 euro gross per share . Sees 2017 revenue, net sales growth up by low to mid single digits .Sees 2017 EBITDA growth in mid single digits.  Full Article

Almirall names David Nieto new CFO as of Feb 1
Wednesday, 4 Jan 2017 04:45am EST 

Almirall S.A. :Names David Nieto as new Chief Financial Officer and Executive Vice President Finance taking effect on Febuary 1st 2017.  Full Article

Almirall signs deal with Mercachem to develop inflammatory skin disease treatment
Wednesday, 21 Dec 2016 05:23am EST 

Almirall SA : Signs exclusive collaboration deal with Mercachem for the development of oral cytokine blockers for the treatment of inflammatory skin diseases .Mercachem will receive a down payment of 1 million euros ($1.04 million) and is entitled to milestone payments of 5.5 million euros.  Full Article

More From Around the Web

BRIEF-Astrazeneca signs deal with Circassia over Almirall's products

* Astrazeneca enters into a strategic collaboration with Circassia for the development and commercialization of Tudorza and Duaklir in the United States